a most interesting discussion.. should Prima go it alone ...an...

a most interesting discussion

.. should Prima go it alone ...

an article just appeared arguing the case for PRR to go it alone

... its the case of Celgene in the US.. who went it alone

an extract of the article follows

" A much more apt comparison, which truly illustrates how the market values earlier stage biotechs, is Celgene (CELG). Celgene is the company on which Dendreon executives have actually publicly said they are modeling their business plan for Dendreon. Celgene's success is based upon its cancer drug Revlimid. Like Dendreon the company decided to go it alone -- declining multiple offers to partner with Big Pharma -- and instead retained 100% worldwide rights to its lead drug. The Celgene plan succeeded fabulously and the company's market cap currently is 26 Billion dollars, based upon revenues of 3.6 Billion dollars. The market-granted multiplier of revenues for Celgene is thus better than 7 times revenues.

Investors should take note that Dendreon is at a much earlier stage in its "follow Celgene" plan -- just ramping up production of Provenge in its first full year of sales and guiding for revenue this year between $350 and $400 million dollars -- but Celgene shares ultimately reached close to a split adjusted share price of 1000, based upon Revlimid's$3.6 billion in sales. "

The full article for those who want to read it is at

http://seekingalpha.com/article/264827-dendreon-is-way-undervalued

... and it wont be too long before we will be reading article like this about Prima... and that will be lifechanging for all when it does